Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAlexandra JungováMGMamta GargIAIrit Avivi

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved survival outcomes in multiple myeloma patients with stem cell transplant, indicating treatment evolution in Europe.

Key Points

  • Median overall survival improved from 74.1 months to not reached from 2012 to 2023, highlighting significant advancements in treatment.
  • Patient outcomes were notably better in those receiving stem cell transplant, with a median survival of 138.4 months compared to 64.2 months without transplant.
  • Survival analysis included over 30,000 patients treated across multiple European countries, emphasizing real-world effectiveness of new therapies.
  • Historical data shows evolving treatment patterns, with a marked shift towards CD38-based regimens translating to enhanced survival rates.

Cite This Study

Jungová et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da6fhttps://doi.org/10.1182/blood-2025-2803
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database2025
  3. 3Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry2025
  4. 4Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience2025
  5. 5Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)2025